Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Jack Khattar Sells 35,000 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack Khattar sold 35,000 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the transaction, the chief executive officer owned 958,100 shares in the company, valued at approximately $48,259,497. This represents a 3.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $50.21 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $59.68. The company has a 50-day moving average of $51.23 and a 200 day moving average of $49.13. The firm has a market cap of $2.89 billion, a PE ratio of -73.84, a price-to-earnings-growth ratio of 1.55 and a beta of 0.70.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Corient Private Wealth LLC purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $237,000. Sit Investment Associates Inc. grew its holdings in Supernus Pharmaceuticals by 0.4% in the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after purchasing an additional 250 shares during the last quarter. Invesco Ltd. grew its holdings in Supernus Pharmaceuticals by 9.4% in the fourth quarter. Invesco Ltd. now owns 395,761 shares of the specialty pharmaceutical company’s stock worth $19,669,000 after purchasing an additional 33,895 shares during the last quarter. Mackenzie Financial Corp acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth $223,000. Finally, Zacks Investment Management acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth $1,807,000.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SUPN shares. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Stifel Nicolaus boosted their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Wall Street Zen cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Supernus Pharmaceuticals has an average rating of “Hold” and an average price target of $62.17.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.